[The testing of the carcinogenicity of dispirotripiperazine derivatives by combined administration with sodium nitrite].
The cancerogenic activity of the dispirotripiperasinium derivatives prospidine and spirobromine was tested in concurrent use with sodium nitrite. The drugs were intragastrically administered once a week. It was combined with sodium nitrite, 35 mg/kg, to non-inbred rats of both sex during 24 months. A morphological study revealed no statistically significant reduction of latency and no increase in the incidence of tumors in laboratory animals. No cancerogenic effect of sodium nitrite was found.
Lavrik
O I
OI
Kinzirskiĭ
A S
AS
Shashkina
L F
LF
Ivanova
V M
VM
Kruglova
O N
ON
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity; D002273:Carcinogens / Q000008:administration & dosage / Q000633:toxicity*; D016009:Chi-Square Distribution; D003043:Cocarcinogenesis; D005260:Female; D015994:Incidence; D008297:Male; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000453:epidemiology; D010879:Piperazines / Q000008:administration & dosage / Q000633:toxicity*; D011447:Prospidium / Q000008:administration & dosage / Q000633:toxicity; D051381:Rats; D012977:Sodium Nitrite / Q000008:administration & dosage / Q000633:toxicity*; D013141:Spiro Compounds / Q000008:administration & dosage / Q000633:toxicity*
D000970:Antineoplastic Agents; D002273:Carcinogens; D010879:Piperazines; D013141:Spiro Compounds; C069536:N,N''-dispirotripiperazine; D011447:Prospidium; C054863:spirobromin; D012977:Sodium Nitrite
Testirovanie kantserogennosti proizvodnykh dispirotripiperaziniia pri kombinirovannom vvedenii s nitritom natriia.